

2014 eMeasure Flows  
Cover Page

**For eligible professionals reporting EHR clinical quality measures for Meaningful Use (MU) only (Option #1) in 2014, the following must be included in the submitted file(s):**


- 1 – Rendering NPI and TIN on QRDA Category III files
- 2 – Payers for all eligible patients identified on QRDA Category III files
- 3 – All of the identifiers for the eMeasures the eligible professional or group practice intends to report must be included in the appropriate fields of the QRDA Category III files even if they do not have any eligible patients for those eMeasures
- 4 – Performance rate(s) (or a measure observation value) must be included in the QRDA Category III file for every eMeasure the eligible professional intended to report according to the performance rate (or measure observation) algorithms provided in each of the flows
- 5 – For every patient evaluated for the eMeasures also identify payer, race, ethnicity and sex.

**For eligible professionals and group practices reporting EHR clinical quality measures for Meaningful Use (MU) and the Physician Quality Reporting System (PQRS) (Option #2) in 2014, the following must be included in the submitted file(s):**

- 1 – Rendering NPI and TIN on the appropriate fields of the QRDA Category I or QRDA Category III files for eligible professionals reporting as *individuals* **OR** submission of all NPIs within the TIN when reporting as a *group practice*
- 2 – At least **one** Medicare Part B beneficiary that is eligible for at least one of the eMeasures either via QRDA Category I or III files
- 3 – Valid HIC# for Medicare beneficiaries on QRDA Category I files
- 4 – Payers for all eligible patients identified on QRDA Category I or III files
- 5 – All of the identifiers for the eMeasures the eligible professional or group practice intends to report must be included in the appropriate fields of the QRDA Category I or III files even if they do not have any eligible patients for those eMeasures
- 6 – Performance rate(s) (or a measure observation value) must be included in the QRDA Category III file for every eMeasure the eligible professional intended to report according to the performance rate (or measure observation) algorithms provided in each of the flows
- 7 – All of the detailed data pertaining to the eMeasures the eligible professional intends to report must be included in the patient-level QRDA Category I files so that the system may generate accurate performance rate(s) (or a measure observation value)
- 8 – For every patient evaluated for the eMeasures also identify payer, race, ethnicity and sex.

2014 eMeasure Flows  
eMeasure Identifier: 140


NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eMeasure to identify the QDM data elements and associated value sets for use in reporting this eMeasure.


2014 eMeasure Flows  
eMeasure Identifier: 140

NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eMeasure to identify the QDM data elements and associated value sets for use in reporting this eMeasure.

2014 eMeasure Flows  
eMeasure Identifier: 140  
NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR)  
Positive Breast Cancer



\*Please refer to the specific section of the eMeasure to identify the QDM data elements and associated value sets for use in reporting this eMeasure.

2014 eMeasure Flows  
eMeasure Identifier: 140  
NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progestosterone Receptor (ER/PR)  
Positive Breast Cancer

**SAMPLE CALCULATION:**

**Performance Rate =**

$$\frac{\text{Numerator (a= 12 patients)}}{\text{Denominator (b=20 patients) - Denominator Exclusions (N/A) - Denominator Exceptions (c^1+c^2+c^3+c^4+c^5+c^6+c^7 =5 patients)}} = 80.00\%$$

2014 eMeasure Flows  
eMeasure Identifier: 140  
NQF 0387: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen  
Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer

Please refer to the specific section of the eMeasure to identify the QDM data elements and associated value sets for use in reporting this eMeasure.

1. Start Initial Patient Population
2. Check Patient Characteristic Sex and Patient Characteristic Birthdate:
  - a. If QDM data element, FEMALE, and the QDM data element, BIRTH DATE, greater than or equal to 18 years starts before start of measurement period equals No, do not include in Initial Patient Population. Stop Processing.
  - b. If QDM data element, FEMALE, and the QDM data element, BIRTH DATE, greater than or equal to 18 years starts before start of measurement period equals Yes, go to check Diagnosis Active..
3. Check Diagnosis Active:
  - a. If First Occurrence A of QDM data element, BREAST CANCER, less than or equal to 5 years starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION during measurement period equals Yes, go to check Encounter Performed.
  - b. If First Occurrence A of QDM data element, BREAST CANCER, less than or equal to 5 years starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, during measurement period equals No, do not include in the Initial Patient Population. Stop Processing.
4. Check Encounter Performed:
  - a. If greater than or equal to 2 counts of QDM data element, OFFICE VISIT, or PATIENT PROVIDER INTERACTION, during measurement period equals Yes, go to Denominator.
  - b. If greater than or equal to 2 counts of QDM data element, OFFICE VISIT, or PATIENT PROVIDER INTERACTION, during measurement period equals No, do not include in the Initial Patient Population. Stop Processing.
5. Start Denominator
  - a. Denominator equals the Initial Patient Population. Go to check Procedure Performed.
6. Check Diagnosis Active:
  - a. If Occurrence A of QDM data element, BREAST CANCER ER OR PR POSITIVE, starts before or during of Occurrence A of Encounter Performed QDM data element OFFICE VISIT OR FACE-TO-FACE INTERACTION but does not start after Occurrence A of QDM data element, BREAST CANCER, equals Yes, proceed to check Procedure Result.
  - b. If Occurrence A of QDM data element, BREAST CANCER ER OR PR POSITIVE, starts before or during of Occurrence A of Encounter Performed QDM data element OFFICE VISIT OR FACE-TO-FACE INTERACTION but does not start after Occurrence A of the QDM data element, BREAST CANCER, equals No, do not include in the Denominator Eligible Population. Stop Processing.

7. Check Procedure Result:
  - a. If Occurrence A of QDM data element CLINICAL STAGING PROCEDURE (result: Breast Distant Metastasis Status M0) starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION but does not start before start of Occurrence A of Diagnosis Active QDM data element BREAST CANCER, equals Yes, proceed to check Procedure Result.
  - b. If Occurrence A of QDM data element CLINICAL STAGING PROCEDURE (result: Breast Distant Metastasis Status M0) starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION but does not start before start of Occurrence A of Diagnosis Active QDM data element BREAST CANCER, equals No, do not include in the Denominator Eligible Population. Stop Processing.
8. Check Procedure Result:
  - a. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Regional Lymph Node Status N3) equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Regional Lymph Node Status N3) equals No, proceed to check Procedure Result.
9. Check Procedure Result:
  - a. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T0 or T1 or T1a or T1b or T1c or T1mi) and (result: Breast Cancer Regional Lymph Node Status N1 or pN1a or pN1b or pN1c or pN1mi or N2), equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T0 or T1 or T1a or T1b or T1c or T1mi) and (result: Breast Cancer Regional Lymph Node Status N1 or pN1a or pN1b or pN1c or pN1mi or N2), equals No, proceed to check Procedure Result.
10. Check Procedure Result:
  - a. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T2 or T3 or T4) and (result: Breast Cancer Regional Lymph Node Status N0 or N1 or N2), equals Yes, include in Denominator Eligible Population. Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.
  - b. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T2 or T3 or T4) and (result: Breast Cancer Regional Lymph Node Status N0 or N1 or N2), equals No, proceed to check Procedure Result.
11. Check Procedure Result:
  - a. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T1c) and (result: Breast Cancer

Regional Lymph Node Status N0), equals Yes, include in Denominator Eligible Population.

Denominator is represented by letter B in the sample calculation listed at the end of this document. Letter B equals 20 patients in the sample calculation.

- b. If Occurrence A of the QDM data element, CLINICAL STAGING PROCEDURE (result: Breast Cancer Primary Tumor Size T1c) and (result: Breast Cancer Regional Lymph Node Status N0), equals No, do not include in Denominator Eligible Population. Stop Processing.

12. Start Numerator

13. Check Medication Order:

- a. If the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes, include in Numerator Count. Numerator is represented by letter A<sup>1</sup> in the sample calculation listed at the end of this document. Letter A<sup>1</sup> equals 4 patients in the sample calculation.
- b. If the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Active.

14. Check Medication Active:

- a. If Occurrence A of the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, equals Yes, include in Numerator Count. Numerator is represented by letter A<sup>2</sup> in the sample calculation listed at the end of this document. Letter A<sup>2</sup> equals 3 patients in the sample calculation.
- b. If Occurrence A of the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, equals No, proceed to check Medication Active.

15. Check Medication Active:

- a. If Occurrence A of the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, equals Yes, include in Numerator Count. Numerator is represented by letter A<sup>3</sup> in the sample calculation listed at the end of this document. Letter A<sup>3</sup> equals 5 patients in the sample calculation.
- b. If Occurrence A of the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during but does not end before start of Occurrence A of Encounter Performed QDM data element, FACE-TO-FACE INTERACTION, equals No, proceed to Denominator Exceptions.

16. Start Denominator Exception

17. Check Procedure Performed:

- a. If the QDM data element, RADIATION THERAPY II, or CHEMOTHERAPY, during measurement period equals Yes, include in Denominator Exception count.



- b. Denominator Exception is represented by letter C1 in the sample calculation listed at the end of this document. Letter C1 equals 1 patient in the sample calculation.
  - c. If the QDM data element, RADIATION THERAPY II, or CHEMOTHERAPY, during measurement period, equals No, proceed to check Medication Order Not Done.
- 18. Check Medication Order Not Done:
  - a. If the QDM data element, MEDICAL REASON, or PATIENT REASON, or SYSTEM REASON, for Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes, include in Denominator Exception count. Denominator Exception is represented by letter C<sup>2</sup> in the sample calculation listed at the end of this document. Letter C<sup>2</sup> equals 1 patient in the sample calculation.
  - b. If the QDM data element, MEDICAL REASON, or PATIENT REASON, or SYSTEM REASON, for Tamoxifen or Aromatase Inhibitor Therapy Grouping Value Set starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Intolerance.
- 19. Check Medication Intolerance:
  - a. If the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception count. Denominator Exception is represented by letter C<sup>3</sup> in the sample calculation listed at the end of this document. Letter C<sup>3</sup> equals 1 patient in the sample calculation.
  - b. If the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Allergy.
- 20. Check Medication Allergy:
  - a. If the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY ALLERGEN, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception count. Denominator Exception is represented by letter C4 in the sample calculation listed at the end of this document. Letter C4 equals 0 patients in the sample calculation.
  - b. If the QDM data element, TAMOXIFEN OR AROMATASE INHIBITOR THERAPY ALLERGEN, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Diagnosis Active.
- 21. Check Diagnosis Active:
  - a. If the QDM data element, INTOLERANCE TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, or METASTATIC SITES COMMON TO BREAST CANCER, or ALLERGY TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception count. Denominator Exception is represented

by letter C5 in the sample calculation listed at the end of this document. Letter C5 equals 1 patient in the sample calculation.

- b. If the QDM data element, INTOLERANCE TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, or METASTATIC SITES COMMON TO BREAST CANCER, or ALLERGY TO TAMOXIFEN OR AROMATASE INHIBITOR THERAPY, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Medication Active.
22. Check Medication Active:
  - a. If the QDM data element, GONADOTROPIN-RELEASING HORMONE ANALOGUE MEDICATION starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes, include in Denominator Exception count. Denominator Exception is represented by letter C6 in the sample calculation listed at the end of this document. Letter C6 equals 0 patients in the sample calculation.
  - b. If the QDM data element, GONADOTROPIN-RELEASING HORMONE ANALOGUE MEDICATION starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Procedure Performed.
23. Check Procedure Performed:
  - a. If the QDM data element, BILATERAL OOPHORECTOMY, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes, include in Denominator Exception count. Denominator Exception is represented by letter C7 in the sample calculation listed at the end of this document. Letter C7 equals 1 patient in the sample calculation.
  - b. If the QDM data element, BILATERAL OOPHORECTOMY, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, proceed to check Patient Characteristic Clinical Trial Participant.
24. Check Patient Characteristic Clinical Trial Participant:
  - a. If the QDM data element, CLINICAL TRIAL PARTICIPANT, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals Yes include in Denominator Exception count. Denominator Exception is represented by letter C7 in the sample calculation listed at the end of this document. Letter C7 equals 1 patient in the sample calculation.
  - b. If the QDM data element, CLINICAL TRIAL PARTICIPANT, starts before or during Occurrence A of Encounter Performed QDM data element, OFFICE VISIT, or FACE-TO-FACE INTERACTION, equals No, include in the No/Missing Data Submitted Count. Stop processing.

#### SAMPLE CALCULATION:

##### Performance Rate =

Numerator (a = 12 patients)

÷

Denominator (b=20 patients) – *Denominator Exclusions (N/A)* – Denominator Exceptions ( $c^1+c^2+c^3+c^4$   $c^5+c^6+c^7$  = 5 patients)

= 80.00%